Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients

Bone Marrow Transplantation

Volumn 27, Issue 8, 2001, Pages 829-835

  Visani, G ^a   Lemoli, R M ^a   Isidori, A ^a   Piccaluga, P P ^a   Martinelli, G ^a   Malagola, M ^a   Gugliotta, L ^b   Bonini, A ^b   Bonifazi, F ^a   Motta, M R ^a   Rizzi, S ^a   Castellani, S ^a   Tura, S ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Division of Hematology   (Italy)

Author keywords

Autologous transplantation; Fludarabine; Myeloid leukemia; Stem cells

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IDARUBICIN; MESNA; MITOXANTRONE; NYSTATIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; IN VIVO STUDY; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ACUTE DISEASE; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW PURGING; CYTARABINE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; MALE; MITOXANTRONE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 17844406127     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703003     Document Type: Article

References (37)

1. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
2. Intensive postremission chemotherapy in adults with acute myeloid leukemia
3. High dose therapy for acute myelocytic leukemia treatment strategy: What is the choice?
4. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study
5. Randomized comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: Results of MRC AML 10 trial
6. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells
7. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukemia due to reinfusion of a higher number of malignant cells
8. Relapse after autografting with peripheral blood stem cells
9. Transplantation of autologous peripheral blood progenitor cells procured after high dose cytarabine based consolidation chemotherapy for adults with acute myelogenous leukemia in first remission
10. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone
11. Autologous peripheral blood stem cell transplantation mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome
12. FLAG (Fludarabine + high dose ara-C + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias
13. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with cytarabine without granulocyte colony-stimulating factor
14. High efficacy of fludarabine containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
15. Proposals for the classification of acute leukemias
16. Report of National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
17. Autologous transplantation of chemotherapy-purged PBSC collection from high-risk leukemia patients: A pilot study
18. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy or related acute myelogenous leukemia
19. Fludarabine containing-regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukemia patients
20. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia
21. + cells to remove circulating tumor cells
22. Autologous PBSCT in acute myeloblastic leukemia and MDS. Evaluation of tumor cell contamination of leukapheresis by cytogenetic and molecular methods
23. Busulphan and cyclophosphamide followed by complete remission: A report from a single institution
24. Non-parametric estimation from incomplete observation
25. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Part II. Analysis and examples
26. Autologous bone marrow transplantation in acute myeloid leukemia in first remission
27. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia
28. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission
29. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: A retrospective study
30. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia
31. High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia
32. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants
33. Cryopreserved autologous bone marrow transplantation in patients with acute nonlymphoid leukemia: Chemotherapy before harvesting is the main factor in delaying the hematological recovery
34. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: Preclinical studies
35. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (ABMT) in standard risk AML: Influence of source and cell composition of the autograft on haemopoietic reconstitution and disease-free survival
36. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia
37. Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia